BRIGHT MINDS BIOSCIENCES INC. (DRUG) — key financial figures for fiscal year 2024 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Net Income/Loss (FY2024)

-CA$2.8M

Total Assets (FY2024)

CA$6.1M

Total Equity (FY2024)

CA$5.5M

Cash Flows from Operating Activities (FY2024)

-CA$1.9M

Source: BRIGHT MINDS BIOSCIENCES INC. 20-F filing (FY2024). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.